HKUST polymer-therapeutics platform entering the clinic in dry eye, with osteoarthritis and aesthetics as follow-on indications.
Polymer-based therapeutics with a first-in-human trial authorised: clinical-stage biotech like BILIX. China-based, so Korean investor fit is unproven.
Evidence from the records
- “Polymer-based therapeutics (ophthalmology, osteoarthritis, regenerativ”
- “First-in-human trial of candidate P002 (dry eye) authorized by Health Canada”
- First step
- Confirm Alpenroute's cross-border biotech appetite via BILIX.